This is a working overview of Preclinical research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
Dihexa is a synthetic peptide that has been examined in laboratory and animal research. Its design is based on angiotensin IV, a naturally occurring peptide fragment produced in the body. The short name dihexa appears in scientific papers and online discussions, while the full chemical name describes a modified peptide chain. It is not a vitamin, mineral, or plant-derived compound. Suppliers typically present it as a research chemical rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS and HPLC | Used for identity and purity assessment. |
| Purity specification | ≥95% or ≥98% in research grades | Actual purity depends on supplier and batch. |
| Stability in solution | Limited; prepare fresh | Aqueous and organic stocks may degrade over time. |
| Recommended storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles. |
| Regulatory status | Not approved for human use | Sold as a research chemical in some regions. |
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
=== Aston Medal === In 1987 the society announce the establishment of the Aston Medal to be awarded to “individuals deserving special recognition by reason of their outstanding contributions to knowledge in the biological, chemical, engineering, mathematical, medical, or physical sciences relating directly to mass spectrometry”.
Tiflorex (TFX), formerly known as flutiorex, is a stimulant amphetamine that was under development as an appetite suppressant in the 1970s, but appears to have been abandoned. It is structurally related to fenfluramine and 4-MTA. Tiflorex went to phase II clinical trials. The extended release formulation "TFX-SR" produced significant suppression of appetite. It also caused slightly more sleep disturbances and headaches than placebo, as well as mydriasis and a self-reported decrease in arousal. It had little effect on heart rate. Tifluorex is claimed to be a more potent anorectic than fenfluramine, with twice its potency in humans and 4 times its potency in rats.
=== February === 2 February – The President of the European Parliament Roberta Metsola began a two-day visit to Ireland. She addressed both Houses of the Oireachtas as part of the 50th anniversary (1 January 1973) of Ireland joining the European Economic Community (now the European Union), and met the president, taoiseach, and tánaiste. 6 February – The Lia Fáil – the coronation stone for the High Kings of Ireland on the Hill of Tara – was vandalised when the word "Fake" was spray painted on the 5,000-year-old granite stone. 7 February Government ministers met with aviation and police authorities for briefing on illegal drone activity at Dublin Airport between 4–6 February which forced suspension of flying and diversions of flights to other airports. Munster Technological University announced that it was investigating a significant breach of its information technology and telephone systems. It was later confirmed that the university suffered a ransomware cyber attack. 9 February An Coimisiún Toghcháin (the Irish electoral commission) was established under the Electoral Reform Act 2022 to oversee elections in Ireland. Microsoft announced that it would cut 120 jobs from its Irish-based workforce as part of a global cost-cutting plan. 12 February – Munster Technological University announced that information stolen from its computer systems in a cyber attack a week ago had appeared on the dark web. 18 February – Up to 50,000 people participated in an "Ireland for All" march and rally in Dublin in support of refugees and asylum seekers, and opposing racism and far-right groups.
== Publications == Robertson published widely over a range of scientific subjects, including his life-long interest in the biochemical processes underlying higher nervous functions and cognition. In 1932, the Australian biochemist, Mary Campbell Dawbarn, compiled an extensive list of Robertson's publications for The Robertson Memorial Volume. She cited 7 books, 174 articles, and 26 other items, published between 1904 and 1929 of which Robertson was joint author. His publications included an early (1914) work, especially written for children; and, later, three significant textbooks, one of which had two editions:
Sources: en.wikipedia.org
Long QT syndrome (LQTS) – Mostly hereditary. On EKG can be observed as longer corrected QT interval (QTc). Characterized by fainting, sudden, life-threatening heart rhythm disturbances – Torsades de pointes type ventricular tachycardia, ventricular fibrillation and risk of sudden cardiac death. Short QT syndrome. Catecholaminergic polymorphic ventricular tachycardia (CPVT). Progressive cardiac conduction defect (PCCD). Early repolarisation syndrome (BER) – common in younger and active people, especially men, because it is affected by higher testosterone levels, which cause increased potassium currents, which further causes an elevation of the J-point on the EKG. In very rare cases, it can lead to ventricular fibrillation and death. Brugada syndrome – a genetic disorder characterized by an abnormal EKG and is one of the most common causes of sudden cardiac death in young men.
Long dsRNA (which can come from hairpin, complementary RNAs, and RNA-dependent RNA polymerases) is cleaved by an endo-ribonuclease called Dicer. Dicer cuts the long dsRNA to form short interfering RNA or siRNA; this is what enables the molecules to form the RNA-Induced Silencing Complex (RISC). Once siRNA enters the cell, it gets incorporated into other proteins to form the RISC. Once the siRNA is part of the RISC complex, the siRNA is unwound to form single-stranded siRNA. The strand that is thermodynamically less stable due to its base pairing at the 5' end is chosen to remain part of the RISC complex. The single-stranded siRNA, which is part of the RISC complex, can now scan and find a complementary mRNA. Once the single-stranded siRNA (part of the RISC complex) binds to its target mRNA, it induces mRNA cleavage. The mRNA is now cut and recognized as abnormal by the cell. This causes degradation of the mRNA and, in turn, no translation of the mRNA into amino acids and then proteins, thus silencing the gene that encodes that mRNA. siRNA is also similar to miRNA; however, miRNAs are derived from shorter stemloop RNA products. miRNAs typically silence genes by repression of translation and have broader specificity of action, while siRNAs typically work with higher specificity by cleaving the mRNA before translation, with 100% complementarity.
The slide shows at (1) an epithelial cell infected by Chlamydia pneumoniae; their inclusion bodies shown at (3); an uninfected cell shown at (2) and (4) showing the difference between an infected cell nucleus and an uninfected cell nucleus. Epithelium grown in culture can be identified by examining its morphological characteristics. Epithelial cells tend to cluster together, and have a "characteristic tight pavement-like appearance". But this is not always the case, such as when the cells are derived from a tumor. In these cases, it is often necessary to use certain biochemical markers to make a positive identification. The intermediate filament proteins in the cytokeratin group are almost exclusively found in epithelial cells, so they are often used for this purpose. Cancers originating from the epithelium are classified as carcinomas. In contrast, sarcomas develop in connective tissue. When epithelial cells or tissues are damaged from cystic fibrosis, sweat glands are also damaged, causing a frosty coating of the skin.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.
Dihexa is often described as an HGF mimetic that activates c-Met signaling. Some research also links it to angiotensin IV pathways. The precise targets and human relevance remain uncertain.
The powder is typically stored at -20 °C, desiccated and protected from light. Avoid repeated freeze-thaw cycles. Follow supplier instructions and institutional guidelines.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.